In his current capacity as Vice President of Research and Translational Biology at Immunome Inc., Fang Shen heads the biology team and oversees a broad-ranging oncology portfolio. A notable tenure as Associate Scientific Director and Group Leader at Janssen R&D, he competently managed a matrixed team and advanced several therapeutic assets into clinical development. This innovative leadership led to his recognition with the Janssen R&D Innovation Leadership Award in 2011 and 2013.
Prior to Janssen, Fang devoted over two years to Genentech, where he made substantial contributions to numerous clinical stage assets, including the BTK inhibitor (GDC-0853). Postdoctoral training under Dr. Sarah Gaffen at SUNY Buffalo afforded him the opportunity to make significant strides in elucidating IL-17 receptor signal transduction. This groundbreaking research won him the Keystone Symposia Scholarship (HHS, NIH & NIAID) in 2005.
Fang’s outstanding academic contributions are exemplified by his authorship of several patents and over 28 publications in prestigious journals.